Daprodustat

Daprodustat, sold under the brand name Duvroq among others, is a medication that is used for the treatment of anemia due to chronic kidney disease. It is a hypoxia-inducible factor prolyl hydroxylase inhibitor. It is taken by mouth. The most common side effects include high blood pressure, thrombotic vascular events, abdominal pain, dizziness, and allergic reactions. Daprodustat was approved for medical use in Japan in June 2020, and in the United States in February 2023. making it the first oral treatment for anemia caused by chronic kidney disease for adults in the US. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Wikipedia contributors, "Daprodustat", Wikipedia, revision 1365572082, retrieved 20 November 2026, source, CC BY-SA 4.0.